This Stock Soared 12% After Its Blowout Earnings Outlook at the End of March, But It's Not Too Late to Buy

Chewy guided to ~8.5% revenue growth at the midpoint for 2026 and expects EBITDA margin to expand to 6.6%–6.8% (up from 5.7% in 2025). Management added 10 Vet Care clinics (total 18), grew private-label offerings (Get Real, Chewy Made), and autoship penetration rose to ~84% of net sales (from 80.6%), supporting loyalty and margin expansion. Sponsored ads materially aided gross margins in 2025 but are expected to taper in 2026. The stock trades at an enterprise value ~12x implied EBITDA despite forecasted EBITDA growth of roughly 25%–30% this year.

Analysis

Chewy’s strategic axis — bundling recurring demand (subscriptions), proprietary SKUs, and on/offline touchpoints — creates optionality that most e-commerce peers lack. The predictable cashflow from subscriptions can be monetized (securitization or working-capital arbitrage), meaning incremental EBITDA should convert to free cash flow faster than headline growth implies; treat any margin improvement as a catalyst for multiple expansion rather than just earnings quality.

Second-order winners include co-packers and private-label ingredient suppliers who will see volume volatility shift from many small CPG customers to fewer large, predictable orders, pressuring spot input markets and squeezing smaller brands’ margins. Conversely, independent veterinary practices and regional retail chains face intensified churn and potential regulatory pushback; expect localized political risk where clinic expansion intersects with professional licensing.

Principal tail risks are execution and unit-economics rollbacks: stepped-up promo activity from larger omnichannel players, slower-than-expected pharmacy cross-sell, or a clamp-down on sponsored-ad take rates could reverse margin progress inside 6–18 months. Also watch capital allocation: accelerating brick-and-mortar vet rollouts is materially more capital-intensive than digital initiatives, and mis-timing that spend could compress ROIC even as revenue grows.

On balance the market likely underprices the structural optionality (subscription monetization + private-label margin capture) but overprices the margin inevitability; the path to a higher long-term multiple is contingent on sustained operating leverage and capital discipline, not just topline acceleration.

Key Decisions for Investors

• Long CHWY equity (size 2–4% portfolio) with 12–18 month horizon — objective: capture multiple re-rating if subscription monetization narrative progresses. Risk: execution miss; set stop-loss at 18–22% drawdown or hedge with short-dated puts if position size exceeds 3%.
• Pair trade: Long CHWY / Short WOOF (equal $ notional) for 9–12 months — expresses share-gain and private-label strength against Petco’s weaker subscription/fulfillment mix. Reward: asymmetric if Chewy converts CLTV faster; risk: sector-wide promo war lifts both — cap notional and rebalance monthly.
• Options collar into a long position: Buy CHWY stock and finance protection by selling 6–9 month out-of-the-money calls (sell calls ~30–40% OTM) while buying puts ~15–20% OTM — reduces net cost and limits downside, capping upside in a controlled band. Use if you want exposure but are wary of near-term volatility.
• Event watch / catalyst trade: Buy modest CHWY call spread 6–12 months (buy nearer-ATM, sell ~40% OTM) ahead of quarterly reports that discuss subscription monetization or vet-clinic KPIs. Target reward 2–3x premium if management proves ARPA/ROIC inflection; max loss limited to premium paid.